Original Articles
27 January 2015

Plasma pharmacokinetics, tissue concentrations and urine elimination after cephalothin intravenous administration to cats under surgical conditions

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
2418
Views
739
Downloads
714
HTML

Authors

Pharmacokinetic profile, tissue concentrations and urine elimination of cephalothin in cats under surgical conditions after a single intravenous dose (30 mg/kg) were studied. Initial plasma concentrations were high [Cp(0), 353.79±118.92 μg/mL], with fast and moderately wide distribution [T1⁄2(d) 0.14±0.10 h] [V(d(ss)) 0.19±0.03 L/kg] and rapid elimination (ClB, 0.16±0.03 L/h.kg; T1⁄2, 1.07±0.23 h; MRT, 1.16±0.21 h). Thirty to 60 minutes after intravenous administration, cephalothin tissue concentrations were in the range of 3.73 μg/g (testicle tissue) to 25.63 μg/g (uterus). Tissue/plasma concentrations rate was in a range of 0.04 (testicle) to 0.21 (uterus). Cephalothin urine elimination was 66.49% in the first 6 hours after administration. Cephalothin plasma concentrations remained above a MIC≥1 μg/mL up to 5.5 hours in all the studied cats. However, for MIC≥8 –μg/mL (MIC breakpoint) this time is reduced to 2.5 hours. This suggests that proper perioperative prophylactic use of cephalothin in cats requires a dose interval not longer than 2 hours.

Altmetrics

Downloads

Download data is not yet available.

Citations

Supporting Agencies

UBACyT 20020100100745, 2011-2014 and UBACyT 20020130100400, 2014-2017

How to Cite



Plasma pharmacokinetics, tissue concentrations and urine elimination after cephalothin intravenous administration to cats under surgical conditions. (2015). Veterinary Science Development, 5(1). https://doi.org/10.4081/vsd.2015.5742